Evercore ISI Starts Cabaletta Bio Inc. (CABA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Cowen Starts Cabaletta Bio Inc. (CABA) at Outperform
November 19, 2019 5:31 AM ESTCowen analyst Phil Nadeau initiates coverage on Cabaletta Bio Inc. (NASDAQ: CABA) with a Outperform rating.
The analyst comments "Cabaletta is one of the first biotechs to use engineered T cell therapies to treat B cell-mediated autoimmune diseases. Lead candidate DSG3-CAART... More
Morgan Stanley Starts Cabaletta Bio Inc. (CABA) at Overweight
November 19, 2019 4:42 AM ESTMorgan Stanley analyst Matthew Harrison initiates coverage on Cabaletta Bio Inc. (NASDAQ: CABA) with a Overweight rating and a price target of $19.00.
For an analyst ratings summary and ratings history on Cabaletta Bio Inc.... More
